TRX103 for Uveitis
(PEACOCX Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.
Who Is on the Research Team?
Quan Nguyen, MD
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a one-time infusion of TRX-103 followed by observation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- TRX103
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Outpatient Infusion of TRX103 followed by outpatient observation period
Infusion of TRX103 followed by 8 hour in patient observation period
Find a Clinic Near You
Who Is Running the Clinical Trial?
Quan Dong Nguyen
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.